# Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

> **NCT01352962** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 18 (actual)

## Conditions studied

- Urethral Neoplasms
- Neoplasms, Urethral
- Cancer of the Urethra
- Urethral Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Carboplatin
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01352962
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-26
- **Primary completion:** 2017-02-07
- **Final completion:** 2018-07-06
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01352962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01352962, "Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01352962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*